DUBLIN--(BUSINESS WIRE)--The "Biopharmaceutical Contract Manufacturing Organization (BCMO) Market, 2022" report has been added to ResearchAndMarkets.com's offering.

This report, Biopharmaceutical Contract Manufacturing Organization (BCMO) Market, 2022, describes and discusses the global contract manufacturing markets, specifically focusing on the production of biotech (large molecule) products including extensive coverage of the biotechnology segment of the global BCMO industry.

Sales estimates are provided by segment and region, expressed in current dollars. Estimates are provided for the historic 2016 to 2021 period and forecasts are provided through 2026.

Further, this report examines third party manufacturing of potential and commercialized prescription drug products throughout the world. Potential drug products are those in clinical (Phase I - Phase III) testing prior to regulatory approval and require relatively small amounts of product for these evaluations; commercialized drugs are those which have received regulatory approval and have been introduced to mass markets. In some cases, drugs have received regulatory approval in selected regions (such as the EU, but not in others such as the US).

The report contains the following market information:

Key Topics Covered:

Chapter 1: Executive Summary

Chapter 2: Overview

Chapter 3: The Contract Manufacturing Industry

Chapter 4: Total Global BCMO Market

Chapter 5: The BCMO Market by Region

Chapter 6: Pharmaceutical & Biotech Company Profiles

For more information about this report visit https://www.researchandmarkets.com/r/664983

More:
World Biopharmaceutical Contract Manufacturing Organization (BCMO) Market Research Report 2022: Focus on Growth Factors - Biotechnology, Biosimilars,...

Comments are closed.